Akebia Therapeutics's major customers
Fresenius Medical Care Rx accounted for 30% of Akebia Therapeutics's revenue in FY 2025, down from 48% a year earlier.
Get an email when Akebia Therapeutics's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Akebia Therapeutics
Customers that Akebia Therapeutics named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Fresenius Medical Care Rx | 30% | ▼ from 48% | 7 years | FY 2025 · filed 26 Feb 2026 |
| U.S.Renal Care | 29% | new | 1 year | FY 2025 · filed 26 Feb 2026 |
| Da VitaDVA | 25% | new | 1 year | FY 2025 · filed 26 Feb 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Otsuka Pharmaceutical | 20% | last FY 2022 | 5 years | FY 2022 · filed 14 Mar 2024 |
| CencoraCOR | 19% | last FY 2024 | 3 years | FY 2024 · filed 26 Feb 2026 |
| AmerisourceBergen | 15% | last FY 2022 | 4 years | FY 2022 · filed 10 Mar 2023 |
| McKessonMCK | 12% | last FY 2024 | 4 years | FY 2024 · filed 26 Feb 2026 |
| Cardinal HealthCAH | 10% | last FY 2023 | 2 years | FY 2023 · filed 26 Feb 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API